Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Does combined clinical and ultrasound assessment allow selection of individuals with rheumatoid arthritis for sustained reduction of anti-tumor necrosis factor therapy?

Marks JL, Holroyd CR, Dimitrov BD, Armstrong RD, Calogeras A, Cooper C, Davidson BK, Dennison EM, Harvey NC, Edwards CJ.

Arthritis Care Res (Hoboken). 2015 May;67(6):746-53. doi: 10.1002/acr.22552.

2.

Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment.

Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS)., Eyre S, Churchman SM, Wilson AG, Isaacs JD, Hyrich K, Barton A, Plant D, Savic S, Cook GP, Sarzi-Puttini P, Emery P, Barrett JH, Morgan AW, McDermott MF.

Ann Rheum Dis. 2014 Jun;73(6):1202-10. doi: 10.1136/annrheumdis-2013-203276. Epub 2013 May 17.

PMID:
23687262
3.

High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis.

Eyre S, Bowes J, Diogo D, Lee A, Barton A, Martin P, Zhernakova A, Stahl E, Viatte S, McAllister K, Amos CI, Padyukov L, Toes RE, Huizinga TW, Wijmenga C, Trynka G, Franke L, Westra HJ, Alfredsson L, Hu X, Sandor C, de Bakker PI, Davila S, Khor CC, Heng KK, Andrews R, Edkins S, Hunt SE, Langford C, Symmons D; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate.; Wellcome Trust Case Control Consortium., Concannon P, Onengut-Gumuscu S, Rich SS, Deloukas P, Gonzalez-Gay MA, Rodriguez-Rodriguez L, Ärlsetig L, Martin J, Rantapää-Dahlqvist S, Plenge RM, Raychaudhuri S, Klareskog L, Gregersen PK, Worthington J.

Nat Genet. 2012 Dec;44(12):1336-40. doi: 10.1038/ng.2462. Epub 2012 Nov 11.

4.

Heterogeneity of anticitrullinated peptide antibodies and response to anti-tumor necrosis factor agents in rheumatoid arthritis.

Fisher BA, Plant D, Lundberg K, Charles P, Barton A, Venables PJ; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS)..

J Rheumatol. 2012 May;39(5):929-32. doi: 10.3899/jrheum.111315. Epub 2012 Apr 1.

PMID:
22467927
5.

Hemorrhagic bullae of the oral mucosa as an early manifestation of vascular-type ehlers-danlos syndrome.

Colebatch AN, Shaw EC, Foulds NC, Davidson BK.

J Clin Rheumatol. 2011 Oct;17(7):383-4. doi: 10.1097/RHU.0b013e31823266a7. No abstract available.

PMID:
21946467
6.

Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis.

Hassan B, Maxwell JR, Hyrich KL; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate., Barton A, Worthington J, Isaacs JD, Morgan AW, Wilson AG.

Rheumatology (Oxford). 2010 Jan;49(1):43-7. doi: 10.1093/rheumatology/kep372. Epub 2009 Nov 19.

PMID:
19926672
7.

Osteomalacia secondary to renal tubular acidosis masquerading as primary biliary cirrhosis.

Davidson BK, Haslock I.

Rheumatology (Oxford). 2000 Dec;39(12):1428-9. No abstract available.

PMID:
11136892
8.

Ten year follow up of pulmonary function in patients with primary Sjögren's syndrome.

Davidson BK, Kelly CA, Griffiths ID.

Ann Rheum Dis. 2000 Sep;59(9):709-12.

9.

Primary Sjögren's syndrome in the North East of England: a long-term follow-up study.

Davidson BK, Kelly CA, Griffiths ID.

Rheumatology (Oxford). 1999 Mar;38(3):245-53.

PMID:
10325663
10.

Myositis associated with griseofulvin therapy.

Davidson BK.

Am Fam Physician. 1995 Oct;52(5):1277. No abstract available.

PMID:
7572547

Supplemental Content

Loading ...
Support Center